Arcadia vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health and value-based care analytics platform aggregating clinical and claims data for health systems and ACOs. Burlington MA, raised $100M+.
About
Arcadia is a healthcare data and analytics company that helps health systems, ACOs, and payers succeed in value-based care arrangements. Headquartered in Burlington, Massachusetts, and having raised more than $100 million from investors including Andreessen Horowitz, Arcadia's platform aggregates clinical data from EHRs, claims data from payers, and social determinants of health data from community sources into a unified longitudinal patient record. This master data layer powers care management workflows, quality measurement, network analytics, and financial performance reporting for value-based care programs.\n\nArcadia's differentiation lies in its ability to normalize and harmonize data from dozens of disparate EHR and claims sources at scale, giving health system leaders and ACO operators a complete and accurate view of their attributed populations. The platform supports MSSP, Medicare Advantage, commercial value-based contracts, and Medicaid managed care programs, helping organizations track performance against quality metrics like HEDIS and CMS Stars while identifying high-risk members for intervention. Embedded care management tools allow clinical teams to act directly on the insights the platform surfaces.\n\nThe company has positioned itself as a strategic analytics partner for complex, multi-entity health systems that cannot rely on a single EHR vendor for population health insights. Arcadia competes with health IT giants like Health Catalyst and Optum as well as specialty vendors, and has continued to grow its customer base among large regional health systems and national provider organizations participating in risk-bearing contracts.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.